About This Calculator

The Keytruda (pembrolizumab) Dosing Calculator is a clinical support tool designed for healthcare professionals to determine appropriate dosing based on patient-specific factors. It simplifies calculations for various FDA-approved indications in both adult and pediatric populations, ensuring alignment with the official prescribing information.

Outputs Explained

Upon entering the required patient information, the calculator provides the following key outputs for a single administration:

• Total Dose to Administer: The final dose in milligrams (mg), calculated based on either a fixed-dose or weight-based regimen. For weight-based dosing, this value reflects the maximum dose cap where applicable.
• Total Volume to Administer: The total volume in milliliters (mL) of Keytruda solution to be prepared for infusion. This is calculated using the standard concentration of 25 mg/mL.
• Regimen Frequency: The recommended interval between infusions, such as every 3 weeks or every 6 weeks.
• Administration Method: Confirms the standard administration route and duration, which is an intravenous infusion over 30 minutes.

How to Use the Dosing Tool

Follow these steps to accurately calculate the Keytruda dose:

1. Enter Patient Weight: Input the patient’s actual body weight. Select the unit of measurement (kg or lbs).
2. Select Patient Population: Choose either “Adult” or “Pediatric” to filter for appropriate dosing regimens.
3. Choose the Indication: Select the relevant cancer diagnosis from the dropdown menu.
4. Select the Dosing Regimen: Based on the indication and population, choose the desired dosing schedule (e.g., 200 mg every 3 weeks).
5. Calculate: The tool will display the calculated dose and volume based on your inputs.

Dosing Overview

Keytruda (pembrolizumab) is administered as an intravenous infusion over 30 minutes. Dosing is dependent on the indication and patient population.

• Adults: The recommended dosage is typically either 200 mg every 3 weeks or 400 mg every 6 weeks for approved indications.
• Pediatrics: For approved indications, the recommended dosage is 2 mg/kg every 3 weeks, with the total dose not to exceed 200 mg.

Always consult the full prescribing information for specific dosing details related to the indication, patient age, and use in combination regimens.

Switching Dosing Schedules

Patients on the 200 mg every 3 weeks (Q3W) schedule may be switched to the 400 mg every 6 weeks (Q6W) schedule, where approved. The first 400 mg dose should be administered at the time the next 200 mg dose was scheduled. This transition does not require a loading dose or washout period.

Missed Dose Guidance

If a planned dose of Keytruda is missed, it should be administered as soon as possible. The subsequent dosing schedule should be adjusted to maintain the correct interval (3 or 6 weeks) from the date the missed dose was administered. Do not administer two doses to make up for a missed one.

Safety Alerts & Dose Modifications

This calculator is not intended for determining dose adjustments due to toxicity. Keytruda can cause severe or fatal immune-mediated adverse reactions. Dosing should be withheld or permanently discontinued as recommended in the prescribing information for suspected adverse reactions.

• Renal Impairment: No dose adjustment is needed for patients with mild or moderate renal impairment. Data is limited for severe renal impairment.
• Hepatic Impairment: No dose adjustment is needed for patients with mild hepatic impairment. Data is limited for moderate or severe hepatic impairment.

Frequently Asked Questions (FAQ)

What patient weight should be used for calculations?

The calculator uses the patient’s actual body weight, as specified in the help text within the tool.

What happens if a calculated pediatric dose exceeds 200 mg?

The pediatric dosing regimen of 2 mg/kg is capped at a maximum of 200 mg per dose. The calculator will automatically apply this cap and show 200 mg as the final dose if the weight-based calculation is higher.

Can I use this for combination therapy dosing?

This tool calculates the dose for the Keytruda (pembrolizumab) component only. When used in combination with other agents like chemotherapy, refer to the respective prescribing information for each agent for its correct dosing and administration.

What concentration of Keytruda is used for the volume calculation?

The calculator uses the standard concentration of Keytruda for injection, which is 25 mg/mL, to determine the total volume to administer.

Is the 400 mg every 6 weeks regimen approved for pediatric patients?

No, based on the approved regimens included in this tool, the 400 mg every 6 weeks schedule is only indicated for adult populations.

How are the approved pediatric indications determined in the calculator?

The tool’s dropdown menu is populated with regimens specifically approved for pediatric patients, including for certain types of Melanoma, Classical Hodgkin Lymphoma, PMBCL, and MSI-H/dMMR solid tumors, among others.

Does the tool provide guidance on dose interruption for toxicity?

No, this tool does not provide guidance for dose modifications related to adverse reactions. Management of immune-mediated adverse reactions may require withholding or discontinuing Keytruda. Refer to the full prescribing information for toxicity management guidelines.

Can a patient be switched from the 3-week to the 6-week schedule?

Yes, for approved adult indications, patients can be switched between the 200 mg Q3W and 400 mg Q6W schedules. Clinical judgment should be used to determine the appropriate schedule for the patient.

References

This information is for educational purposes. All clinical decisions must be based on the most current, official prescribing information.

1. KEYTRUDA® (pembrolizumab) Prescribing Information. U.S. Food and Drug Administration. October 2023.
2. KEYTRUDA® Full Prescribing Information. Merck & Co., Inc.
3. KEYTRUDA® for Healthcare Professionals. Merck & Co., Inc.
4. Drugs@FDA: FDA-Approved Drugs – KEYTRUDA (pembrolizumab). U.S. Food and Drug Administration.